Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news that the Company has now reported the full data set of its Phase 2a Study of Ifenprodil for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Cough.
Mr. Moreau explains to Proactive that the Company saw positive data from this study which measured efficacy in lung function and patient-reported outcomes of both IPF and Chronic Cough. The data showed statistically significant improvements in measures of cough. As for IPF, 65% of patients had stable or improved FVC over the 12-week treatment period with statistical significance when compared to an anticipated placebo effect. Mr. Moreau discusses these and other key indicators from the study.